Timber Pharmaceuticals — Investor Presentation (June 2022)
34 slides from Timber Pharmaceuticals's investor presentation, Jun 10, 2022
Slide 1: Building Bridges in Medical Dermatology
Building Bridges in Medical Dermatology Investor Presentation June 2022 NYSE American: TMBR
Slide 2: Safe Harbor Statement
NYSE American: TMBR Safe Harbor Statement 2 Certain statements contained in this PowerPoint presentation describing Timber’s technology and development program, including, without limitation, statements containing the words “expects,” “anticipates,” “believes,” and words of similar import, constitut
Slide 3: Timber Pharmaceuticals company description
NYSE American: TMBR 3 3 NYSE American: TMBR Timber Pharmaceuticals is a specialty pharmaceutical company devoted to transforming the lives of patients with rare, high impact dermatologic diseases by utilizing advanced translational science.
Slide 4: Business Model Focused on Orphan Drug Indications and 505(b)(2) Pathway
NYSE American: TMBR Timber Business Model 4 Focused on Orphan Drug Indications and Leveraging the 505(b)(2) pathway • Timber can be first to market by pursuing conditions for which there are no current FDA approved treatments • Requires potentially smaller and less costly drug trials with greater fl
Slide 5: Investment Highlights
NYSE American: TMBR Investment Highlights 5 • Positioning to become a leading rare disease dermatology company with a focus on rare and orphan dermatologic diseases, led by a management team with a proven track record in development and commercialization • Lead product candidate TMB - 001 achieved m
Slide 6: Strategic Pipeline in Rare Dermatologic Disease
NYSE American: TMBR 6 Strategic Pipeline in Rare Dermatologic Disease TMB - 001 Received FDA Breakthrough Therapy Designation in May 2022
Slide 7: Topical Isotretinoin for Moderate to Severe Congenital Ichthyosis
NYSE American: TMBR 7 7 NYSE American: TMBR TMB - 001 – Topical Isotretinoin Moderate to Severe Congenital Ichthyosis (CI)
Slide 8: Received Multiple FDA Milestones
NYSE American: TMBR 8 TMB - 001 has Received Multiple FDA Milestones May 2022 – FDA Breakthrough therapy status granted • A process designed to expedite the development and review of drugs that are intended to treat serious or life - threatening conditions April 2022 – FDA Fast Track designation
Slide 9: Unmet Need: Safe Long-Term Treatment for Congenital Ichthyosis
NYSE American: TMBR Unmet Need: An efficacious and safe treatment that can be used long term to cover a large body surface area .. 9 Congenital Ichthyosis – Quick facts A rare disorder of keratinization affecting ~ 80,000 people in the U.S. and >1.5 million globally Prevalence • X - Linked Ichthyo
Slide 10: Topical Isotretinoin in CI
NYSE American: TMBR 10 TMB - 001 - Topical Isotretinoin in CI Patented topical formulation that minimizes systemic absorption, thereby allowing for chronic treatment Isotretinoin is well known as the most effective therapy for several skin conditions, including ichthyosis, but it is only available
Slide 11: Phase 2b Study Design
NYSE American: TMBR 11 TMB - 001 Phase 2b Study Design Title A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB - 001 for Treatment of Congenital Ichthyosis Primary Objective Proportion of subjects with Visual Index of Ichthyosis Severity (VIIS) treatment success, defined as 5
Slide 12: CONTROL Study - Efficacy Per Protocol
NYSE American: TMBR 12 TMB - 001 CONTROL Study - Efficacy Per Protocol 100% of the Per Protocol Population in 0.05% dose achieved a 50% reduction in VIIS score versus 40% in the vehicle group (nominal p=.04) 100% of the Per Protocol Population in 0.05% dose achieved a 2 point reduction in IGA versus
Slide 13: CONTROL Study - Efficacy Intent to Treat
NYSE American: TMBR 13 TMB - 001 CONTROL Study - Efficacy Intent to Treat (ITT) 64% of the ITT Population in 0.05% dose achieved a 50% reduction in VIIS score versus 33% in the vehicle group (nominal p=.17) 55% of the ITT Population in 0.05% dose achieved a 2 point reduction in IGA versus. 8% in the
Slide 14: CONTROL Study patient with Lamellar Ichthyosis (0.05% arm)
NYSE American: TMBR 14 TMB - 001 CONTROL Study 21 year old patient with Lamellar Ichthyosis (ALOX12B) - 0.05% arm (responder) End Of Study – Visit 6 Baseline
Slide 15: CONTROL Study patient with Lamellar Ichthyosis (0.05%)
NYSE American: TMBR 15 TMB - 001 CONTROL Study 39 year old patient with Lamellar Ichthyosis (0.05%) End Of Study – Visit 6 Baseline
Slide 16: Phase 3 ASCEND Study Design
NYSE American: TMBR 16 TMB - 001 Phase 3 Study Design Title The ASCEND Study: A Phase 3, Multicenter, Double Blind Vehicle Controlled Study of TMB - 001 with a parallel Optional Maximal Use Arm - in the treatment of RXLI or ARCI Ichthyosis in Subjects Aged > 6 Years Primary Objectives • To ascertain
Slide 17: Topical Rapamycin and Topical Sitaxsentan Programs
NYSE American: TMBR 17 17 NYSE American: TMBR TMB - 002 – Topical Rapamycin Facial Angiofibromas (FAs) in Tuberous Sclerosis Complex (TSC) TMB - 003 - Topical Sitaxsentan Sclerotic Skin Diseases
Slide 18: TMB-002 Topical Rapamycin (Pascomer)
NYSE American: TMBR 18 TMB - 002 Topical Rapamycin (Pascomer®) Pascomer® is being developed for territories outside of the United States where Facial Angiofibromas remain a high unmet need. Proprietary topical formulation of rapamycin (1.0%, 0.5%, and 0.1%) • Additional 5% strength assessed in p
Slide 19: TMB-002 for Facial Angiofibromas in Tuberous Sclerosis Complex
NYSE American: TMBR 19 TMB - 002 for Facial Angiofibromas in Tuberous Sclerosis Complex TSC is a multisystem genetic disorder affecting approximately 50,000 people in the U.S. TSC is caused by the unregulated activation of the mammalian target of rapamycin (mTOR) pathway, resulting in the growth o
Slide 20: TMB-002 Phase 2b Study Design
NYSE American: TMBR 20 TMB - 002 Phase 2b Study Design Title Dose - Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibromas Associated With Tuberous Sclerosis Complex Primary Objective • Proportion of subjects with IGA treatment success defined as clear or almost clear
Slide 21: TMB-003 Topical Sitaxsentan for Sclerotic Skin Diseases
NYSE American: TMBR 21 TMB - 003 Topical Sitaxsentan for Sclerotic Skin Diseases Highly Selective ET - A inhibitor Sitaxsentan is a highly selective (6,500:1) ET - A receptor antagonist. • It was previously on the market in the E.U., Canada and Australia as an oral treatment for PAH but was volunt
Slide 22: Lichen Sclerosis
NYSE American: TMBR 22 Lichen Sclerosis Rare chronic disease of vulvae and perianal areas which affects approximately 160,000 women in the U.S.* Lichen Sclerosis affects both sexes, but is predominant in women • Prevalence 0.1 - 1.7% of women; diagnosed more by gynecologists than dermatologists •
Slide 23: Scleroderma
NYSE American: TMBR 23 Scleroderma Rare connective tissue disorder characterized by abnormal thickening of the skin Two potential markets: • Moderate to Severe Localized Scleroderma which generally only affects the skin • More common in children, with a prevalence of approximately 90,000 people in
Slide 24: Multiple Barriers to Entry
NYSE American: TMBR Multiple Barriers to Entry 24 Orphan exclusivity granted for all three strategic assets • 7 years in U.S., 10 years in E.U. and Japan Patents granted and pending globally Trade secrets in formulation/manufacturing • Cytotoxic, requires containment, photolabile, prone to oxi
Slide 25: World Class Clinical Advisors and Partners
NYSE American: TMBR World Class Clinical Advisors and Partners 25 • Amy S. Paller , MD Chair and Professor of Dermatology and Pediatrics, Northwestern University • Keith Choate, MD, PhD Professor of Dermatology, Pathology, and Genetics, Yale University • Joyce Teng, MD Professor and Director of Pedi
Slide 26: John Koconis, Chairman and CEO; Alan Mendelsohn, CMO
NYSE American: TMBR John Koconis, MBA, Chairman and CEO • Seasoned Pharmaceutical executive with over 25 years experience leading successful teams in global markets and having launche d multiple market leading products in Dermatology • President & CEO of LEO Pharma (U.S.), established a market leadi
Slide 27: Joseph Lucchese, CFO and Clinical Operations leadership
NYSE American: TMBR Joseph Lucchese, CFO • Chief Financial Officer of Timber Pharmaceuticals • Founding member and Managing Director of Oncology Partners; Managing Director at BlueStone Capital Partners, headed the Private Placement desk • Portfolio Manager and Chief Financial Officer of the MicroCa
Slide 28: Independent Board of Directors
NYSE American: TMBR Independent Board of Directors 28 Lead Independent Board Member Respected expert in SEC reporting and internal controls with extensive financial leadership experience as CFO at several public life sciences companies. Independent Board Member Professor of Dermatology at New York U
Slide 29: Key Takeaways
NYSE American: TMBR Key Takeaways 29 Rare, High Need Medical Dermatology Large Market Potential Multiple Shots on Goal De - Risked Portfolio Management Expertise • High unmet needs with large market potential • All strategic programs have been granted Orphan Drug status • No approved treatments for
Slide 30: Investor Contact Information
www.timberpharma.com For additional Investor Information please contact: John Koconis Stephanie Prince Chairman and CEO PCG Advisory [email protected] [email protected] (646) 863 - 6341 NYSE American: TMBR
Slide 31: APPENDIX/Additional Slides
www.timberpharma.com APPENDIX/Additional Slides NYSE American: TMBR
Slide 32: Topical Isotretinoin in CI
NYSE American: TMBR 32 TMB - 001 Topical Isotretinoin in CI Baseline Day 57 Day 84 2 3 1 Vehicle TMB - 001 (0.1%) TMB - 001 (0.1%) TMB - 001 (0.1%) Percent of Subjects Achieving a 2 - point Reduction on Day 57 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% IGA Scaling Vehicle Active 0.1% Primary measure was
Slide 33: CONTROL Study X-linked patient (0.1%)
NYSE American: TMBR 33 TMB - 001 CONTROL Study - 21 year old X - linked (0.1%) End Of Study – Visit 6 Baseline
Slide 34: Condensed Balance Sheet March 31, 2022
NYSE American: TMBR Condensed Balance Sheet 34 March 31, 2022 Cash $13,860,273 Other Current Assets $211,227 Total Current Assets $14,071,500 Other Assets $708,879 Total Assets $14,780,379 Total Current Liabilities* $3,908,287 Long - Term Debt -- Lease Liability $241,507 Other Liabilities $73,683 To
Timber Pharmaceuticals — Investor Presentation (June 2022) on 6ix